April 16, 10:00 AM Melbourne Time
Accelagen and Griffith University are excited to invite you to an exclusive webinar discussing a world-first clinical trial that could redefine spinal cord injury (SCI) treatment. This event will provide insights into the innovative cell-based therapy being tested, the requirements and challenges of managing such a complex trial, and how Australia provides an attractive environment for efficient and effective clinical trial outcomes.
Webinar Description:
The Australian medical research community continues to push the boundaries of innovation, rapidly translating cutting-edge therapies from the lab to patients with the support of a well-established clinical trials sector. In this exclusive webinar, Accelagen will describe what it takes to progress new medical therapies to the clinic in Australia, introducing its partners from Griffith University who are leading a groundbreaking clinical trial for spinal cord injury treatment as a case study.
Join this webinar to learn how a novel cell therapy technology is advancing with the support of Australia’s world-class regulatory framework and research infrastructure. Discover how Accelagen, a leading Australian CRO, is playing a crucial role in guiding and accelerating this transformative therapy from discovery to human trials—offering new hope for patients worldwide. Don’t miss this opportunity to gain insights into a potential game-changer in spinal cord injury treatment and to understand the experience and leadership required to take the innovative approach into trials.
A Revolutionary Approach to SCI Treatment
Spinal cord injuries have long been among the most challenging medical conditions to treat, often resulting in permanent disability. This Phase I clinical trial explores the use of olfactory ensheathing cells (OECs)—specialised cells from the nose known for their nerve repair properties – to stimulate repair and bring hope of recovery to patients. By harvesting and reintroducing these cells into the injury site, researchers aim to bridge damaged nerve tissues, stimulate regeneration, and restore lost functions, such as mobility and sensation.
Webinar Highlights
1.) Exclusive Insights from Leading Experts
– Learn directly from Professor James St John, the lead researcher at Griffith University, about the years of discovery research leading to this trial.
– Hear from Accelagen’s clinical trial specialists on the unique challenges and strategies involved in bringing this novel therapy to patients.
2.) Understanding the Clinical Trial Process
– Gain an overview of how this innovative study is being conducted.
– Learn about the regulatory, ethical, and logistical considerations in running a world-first cell therapy trial and the advantages of running trials in Australia.
3.) The Future of SCI Treatment
– Explore how this research could revolutionise not just SCI treatment, but also other neurodegenerative conditions.
– Find out what’s next in the journey toward making this therapy widely available.
Why Attend?
– Stay informed about one of the most promising advances in regenerative medicine.
– Engage with experts leading the charge in SCI treatment innovation.
– Discover how Australia is positioning itself as a global leader in cutting-edge biomedical research with the leadership of experienced clinical trial experts.
This is a must-attend event for researchers, healthcare professionals, SCI patients, advocacy groups, and anyone interested in the latest breakthroughs in medical science.
Don’t miss this opportunity to be part of a conversation that could change lives.
📅 Date: April 16, 2025
⏰ Time: 10:00 AM (Melbourne Time)